ELREXFIO: Blood cancer drug meets main goal in late-stage trial
Key takeaways
- Add ARY News on Google Pfizer said on Wednesday its drug Elrexfio met the main goal in a late-stage trial that tested the blood cancer treatment in patients who received at least one prior line of treatment.
- About Multiple Myeloma Multiple myeloma is an aggressive and currently incurable blood cancer that affects plasma cells made in the bone marrow.
Why this matters: local context for readers following news across Pakistan and the region.
Add ARY News on Google Pfizer said on Wednesday its drug Elrexfio met the main goal in a late-stage trial that tested the blood cancer treatment in patients who received at least one prior line of treatment.
About Multiple Myeloma Multiple myeloma is an aggressive and currently incurable blood cancer that affects plasma cells made in the bone marrow. Healthy plasma cells make antibodies that help the body fight infection.6 While disease trajectory varies for each person, relapses are nearly inevitable.9 The goal of therapy for people with relapsing or refractory multiple myeloma is to achieve disease control with acceptable toxicity and improved quality of life.
About ELREXFIO (elranatamab) ELREXFIO is a subcutaneously delivered B-cell maturation antigen (BCMA)-cluster of differentiation CD3-directed bispecific antibody immunotherapy that binds to BCMA on myeloma cells and CD3 on T cells, activating the T cells to kill myeloma cells.